2. Academic Validation
  3. Smyd3 regulates cancer cell phenotypes and catalyzes histone H4 lysine 5 methylation

Smyd3 regulates cancer cell phenotypes and catalyzes histone H4 lysine 5 methylation

  • Epigenetics. 2012 Apr;7(4):340-3. doi: 10.4161/epi.19506.
Glenn S Van Aller 1,  Nicolas Reynoird,  Olena Barbash,  Michael Huddleston,  Shichong Liu,  Anne-Flore Zmoos,  Patrick McDevitt,  Robert Sinnamon,  BaoChau Le,  Gloria Mas,  Roland Annan,  Julien Sage,  Benjamin A Garcia,  Peter J Tummino,  Or Gozani,  Ryan G Kruger
Affiliations

Affiliation

  • 1 GlaxoSmithKline, Collegeville, PA, USA.
PMID: 22419068 DOI: 10.4161/epi.19506
Abstract

SMYD3 is a lysine methyltransferase implicated in chromatin and Cancer regulation. Here we show that SMYD3 catalyzes histone H4 methylation at lysine 5 (H4K5me). This novel histone methylation mark is detected in diverse cell types and its formation is attenuated by depletion of SMYD3 protein. Further, Smyd3-driven Cancer cell phenotypes require its enzymatic activity. Thus, SMYD3, via H4K5 methylation, provides a potential new link between chromatin dynamics and neoplastic disease.

Figures